TRVXo

Targovax

Market Cap 1,210.0M

Targovax är ett nordiskt bioteknikbolag med huvudkontor i Oslo, Norge, verksamhet i Finland, en norsk verkställande direktör, Øystein Soug, och en svensk forskningschef, Magnus Jäderberg. Verksamheten är inriktad på forskning och utveckling av nya immunterapier för behandling av cancer, vilket sker utifrån två separata plattformar; en cancervaccinplattform med inriktning på mutationer av RAS-protein och en plattform av modifierade onkolytiska virus. Nuvarande bolagsstruktur blev till i juni 2015 när norska Targovax köpte finska Oncos Therapeutics. Samgåendet har skapat ett bolag med en bredare projektportfölj, varav tre aktiva projekt i klinisk fas.

+ more
0.00
Today
Day High
N/A
23
Day Low
N/A
Day Open
22.90
Prev Close
23.00
VWAP
N/A
Volume
0K
Turnover
0.000M
Top Broker
VWAP
nan
Avg Volume
Avg Turnover
Top Brokers
VWAP
nan
Avg Volume
Avg Turnover
Top Brokers
VWAP
nan
Avg Volume
Avg Turnover
Top Brokers
52 week summary
Price Range
N/A
Last
N/A
Beta
N/A
Market Cap
1,210.0M
Total Return
0.0%
Trailing P/E
-7.9
Div Yield
0.0%
Shares Outstanding
52.6M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months N/A%
Change 12 Months N/A%
Volume Trend
Average Volume 10 vs 60 Days
Price VS
52 Week High
50 Day Moving Average
200 Day moving Average

Add article markers

Compare Targovax to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Öystein Soug, CEO
  • Erik Digman, CFO
  • Executive board
  • Patrick Vink, Chairman of the board
  • Bente-Lill Romøren
  • Johan Christenson
  • Per Samuelsson
  • Robert Burns
  • Eva-Lotta Allan
  • Diane Mellett
  • Jónas Einarsson
Last updated: 2018-02-15 Source: Redeye
Major Owners Equity Votes
Healthcap 23.6%
23.6%
Radiumhospitalets Forskningsstiftelse 8.4%
8.4%
VPF NORDEA KAPITAL 3.3%
3.3%
NORDNET LIVSFORSIKRING AS 3.0%
3.0%
VPF NORDEA AVKASTNING 3.0%
3.0%
KLP AKSJENORGE 1.9%
1.9%
NORDNET BANK AB 1.7%
1.7%
STATOIL PENSJON 1.6%
1.6%
DANSKE BANK A/S 1.6%
1.6%
THORENDAHL INVEST AS 1.5%
1.5%
Last updated: 2017-09-10 Source: Redeye/Holdings
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (NOK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (NOKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(NOKm)
  • Capital employed(NOKm)
  • Capital turnover rate
  • (NOKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (NOKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (NOKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 0.0%
  • -57.9%
  • 0.0%
  • -24,388.9%
  • -24,404.2%
  • -24,511.1%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -62.6
  • 0.0
  • 0.0
  • 0.0
  • -868.8
  • 3.6
  • 3.6
  • 0.0
  •  
  • 90.1%
  • 0.0%
  • -63
  • -2
  • 0.0
  • 2014
  •  
  •  
  • 63
  • 5
  • 0
  • 0
  • 67
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 67
  •  
  •  
  • 0
  • 3
  • 3
  • 7
  • 0
  • 0
  • 0
  • 7
  • 0
  • 0
  • 61
  • 0
  • 61
  • 67
  • 2014
  • 0
  • -18
  • 0
  • -18
  • 0
  • -18
  • 0
  • -18
  • 2
  • 0
  • -16
  • 2014 Q3
  • 0
  • -18
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2014 Q4
  • 0
  • -18
  • -18
  • 0
  • 0
  • 0
  • -18
  • 0
  • 0
  • 0
  • -18
  • 0
  • -18
  • 2015
  •  
  • -38.0%
  • -34.4%
  • 4,871.9%
  • -61,281.5%
  • -61,382.9%
  • -62,889.0%
  •  
  • -3.42
  • -3.42
  • 0.00
  •  
  • 26.9
  •  
  • -135.8
  • 0.0
  • 0.0
  • 0.0
  • -930.0
  • 1.5
  • 1.5
  • 0.0
  •  
  • 77.6%
  • 100.0%
  • -136
  • 287
  • 0.0
  • 2015
  •  
  •  
  • 174
  • 12
  • 0
  • 0
  • 185
  •  
  • 2
  • 0
  • 0
  • 0
  • 358
  • 0
  • 0
  • 360
  • 0
  • 545
  •  
  •  
  • 0
  • 8
  • 17
  • 25
  • 38
  • 0
  • 0
  • 64
  • 59
  • 0
  • 423
  • 0
  • 423
  • 545
  • 2015
  • 0
  • -90
  • 0
  • -90
  • -2
  • -92
  • 0
  • -91
  • 12
  • -360
  • -381
  • 2015 Q1
  • 0
  • -90
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • -90
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • -90
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 0
  • -90
  • -89
  • 0
  • 0
  • 0
  • -90
  • 0
  • 0
  • 0
  • -90
  • -2
  • -92
  • 2016
  •  
  • -29.7%
  • -27.2%
  • -41.5%
  • -322,232.4%
  • -323,000.0%
  • -330,913.5%
  •  
  • -2.90
  • -2.90
  • 0.00
  •  
  • 42.2
  •  
  • 363.8
  • -4.0
  • -4.0
  • 13,398.2
  • 9,832.9
  • -3.1
  • -3.0
  • 1.2
  •  
  • 76.4%
  • 7.4%
  • -132
  • 269
  • 0.0
  • 2016
  •  
  •  
  • 172
  • 14
  • 0
  • 0
  • 186
  •  
  • 1
  • 0
  • 0
  • 0
  • 338
  • 0
  • 0
  • 340
  • 0
  • 525
  •  
  •  
  • 0
  • 8
  • 21
  • 29
  • 40
  • 0
  • 0
  • 69
  • 55
  • 0
  • 401
  • 0
  • 401
  • 525
  • 2016
  • 0
  • -119
  • 0
  • -120
  • 0
  • -119
  • 0
  • -119
  • 1
  • 20
  • -101
  • 2016 Q1
  • 0
  • -31
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • -1
  • 0
  • -32
  • 0
  • -31
  • 2016 Q2
  • 0
  • -32
  • -32
  • 0
  • 0
  • 0
  • -32
  • 0
  • -1
  • 0
  • -33
  • 0
  • -33
  • 2016 Q3
  • 0
  • -25
  • -25
  • 0
  • 0
  • 0
  • -25
  • 0
  • -1
  • 0
  • -26
  • 0
  • -26
  • 2016 Q4
  • 0
  • -31
  • -31
  • 0
  • 0
  • 0
  • -31
  • 0
  • -1
  • 0
  • -32
  • 0
  • -32
  • 2017 E
  • 2017 E
  • 2017 E
  • 2017 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-08-31 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.

Community Posts

Be the first to write something about this company in the community.

Create new post